Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm
2020; American Medical Association; Volume: 3; Issue: 6 Linguagem: Inglês
10.1001/jamanetworkopen.2020.7410
ISSN2574-3805
AutoresSaketh R. Guntupalli, Alyse Brennecke, Kian Behbakht, Anna Tayebnejad, Christopher Breed, Lisa Marie Babayan, Georgina Cheng, Amin A. Ramzan, Lindsay W. Brubaker, Bradley R. Corr, Carolyn Lefkowits, Jeanelle Sheeder, Koji Matsuo, Dina M. Flink,
Tópico(s)Blood Coagulation and Thrombosis Mechanisms
ResumoCurrent guidelines recommend a 28-day course of enoxaparin for thromboprophylaxis after surgery for gynecologic cancer. The high cost of this medication and the low adherence rates observed in prior studies provide an opportunity to benefit patients by demonstrating the safety of a more cost-effective, easier to use thromboprophylactic.
Referência(s)